AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed ...

The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. Read More on ABBV: AbbVie NewsMORE Related Stocks Indices Commodities ...

Steve Grzanich has the business news of the day with the Wintrust Business Minute. Shares of AbbVie have dropped sharply ...

In the EMPOWER trials, emraclidine was well-tolerated with a safety profile comparable to that observed in the Phase 1b trial. The most commonly reported adverse events in EMPOWER-1 and EMPOWER-2, ...

Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...

The foundation donation will go toward construction of UChicago Medicine's $815 million freestanding cancer care center in ...

“We’re really excited and proud to have the opportunity to support University of Chicago Medicine and the South Side ...

AbbVie and Aliada Therapeutics have announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology ...

Evolveimmune Therapeutics Inc. has secured its fourth big pharma investor and its first pharma development partnership in a ...

EvolveImmune Therapeutics Inc., a Branford-based bioscience company developing therapeutics to overcome cancer cell ...